BioNTech
BNTX
260 hedge funds and large institutions have $5.72B invested in BioNTech in 2025 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 85 increasing their positions, 82 reducing their positions, and 51 closing their positions.
36% more capital inflows, than outflows
Capital inflows: $835M | Capital outflows: $614M
4% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 82
0.79% more ownership
Funds ownership: 21.58% → 22.37% (+0.79%)
8% less funds holding
Funds holding: 282 → 260 (-22)
17% less call options, than puts
Call options by funds: $150M | Put options by funds: $180M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
37% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$355M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$88.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$88.4M |
| 4 |
Bank of New York Mellon
New York
|
+$41.4M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$80.1M |
| 2 |
Millennium Management
New York
|
-$55M |
| 3 |
BlackRock
New York
|
-$35.5M |
| 4 |
Temasek Holdings
Singapore
|
-$30.4M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$29.8M |
BNTX Hedge Fund Activity: Q2 2025 in Review
260 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2025, worth a combined $5.72B — up 21% from $4.72B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of BNTX and 32 opened new positions — a net loss of 19 holders — while 82 trimmed existing stakes and 85 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $355M. The largest seller was Viking Global Investors, exiting entirely with an estimated $80.1M sold.
- 260 institutional investors held BioNTech (BNTX) as of Q2 2025, down from 282 in Q1 2025.
- Funds reported $5.72B of BioNTech stock for Q2 2025, up 21% quarter-over-quarter.
- 32 funds opened new BioNTech positions in Q2 2025 and 51 closed out, a net change of -19 holders.
- The largest BioNTech buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $355M added.
- The largest BioNTech seller in Q2 2025 was Viking Global Investors, an estimated $80.1M sold.
Based on aggregated 13F filings for Q2 2025.